Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 216 clinical trials
Featured trial
l Investigation of Robotic-assisted TKA (RA-TKA) With Skywalker and Evolution Medial Pivot Knee (eMP Knee) (123)

This is a prospective trial that attempts to develop evidence on the safety and performance of RA-TKA (Robotic-assisted total knee arthroplasty) with Skywalker and eMP (Evolution Medial Pivot) knee. Moreover to evaluate performance of eMP patients with Skywalker (in comparison to eMP with conventional instrumentations and non-MP TKAs)

Online studies
Accepts healthy volunteers
  • 0 views
  • 16 May, 2025
  • Online study
Featured trial
Test RTE

Study Overview Study Details Eligibility Trial Primary Objective:
To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to severe atopic dermatitis (AD)
Secondary Objectives:
To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation
To continue to …

  • 0 views
  • 19 Feb, 2024
Featured trial
Study on the Visual Condition in Parkinson's Disease  

Non motor symptoms and signs in Parkinson's disease (PD) also include a series of visual deficits; deepening these aspects could be useful for a better management of symptoms, to standardize a specific protocol for the issues related to vision and also to understand how these aspects are important for the …

motor symptoms
parkinson's disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707)  

ul>

  • 0 views
  • 04 Apr, 2025
  • 1 location
  • Online study
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (ZEN)

This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years.

Study details include:

<ul>
  • Screening period: up to 4 weeks (30 days)
  • Treatment duration: up to 16 weeks
  • Follow-up period: …

    • 0 views
    • 09 May, 2025
    SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients  

  • The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
    • ul>

    …

    pulmonary metastasis
    measurable disease
    stage iv non-small cell lung cancer
    small cell lung cancer
    non-squamous non-small cell lung cancer
    • 0 views
    • 19 Feb, 2024
    • 52 locations
    A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

    Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:-

    <ul>
  • Arm A: Tiragolumab plus atezolizumab and CE
  • Arm B: Placebo plus atezolizumab and CE
    • ul>

    Following the induction phase, participants will continue maintenance therapy with either atezolizumab …

    measurable disease
    solid neoplasm
    atezolizumab
    extensive stage small cell lung cancer
    small cell lung cancer
    • 0 views
    • 19 Feb, 2024
    Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

  • The investigational treatment duration will be up to approximately 52 weeks.
  • The number of visits will be 18.
    • ul>

    • 0 views
    • 15 May, 2025
    Determination of the Optimal Treatment Target in Ulcerative Colitis

    Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as:

    <ul>
  • Group 1: corticosteroid-free symptomatic remission
  • Group 2: corticosteroid-free endoscopic + symptomatic remission
  • Group 3: corticosteroid-free histological + endoscopic …

    remission
    ulcerative colitis
    colitis
    corticosteroids
    tuberculosis
    • 0 views
    • 19 Feb, 2024
    A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

    ul>

    b-cell lymphoma
    fludarabine
    malt
    leukapheresis
    alkylating agents
    • 0 views
    • 19 Feb, 2024